<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51B3600A-54C2-4F6B-99AE-03CD7220EBBA"><gtr:id>51B3600A-54C2-4F6B-99AE-03CD7220EBBA</gtr:id><gtr:name>Royal College of Surgeons in Ireland</gtr:name><gtr:address><gtr:line1>Academic Centre</gtr:line1><gtr:line2>Coombe Women's Hospital</gtr:line2><gtr:line3>Dublin 8</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3923DFCB-BCB6-4B65-BA04-DBFFDD0A5B22"><gtr:id>3923DFCB-BCB6-4B65-BA04-DBFFDD0A5B22</gtr:id><gtr:name>British Lung Foundation (BLF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51B3600A-54C2-4F6B-99AE-03CD7220EBBA"><gtr:id>51B3600A-54C2-4F6B-99AE-03CD7220EBBA</gtr:id><gtr:name>Royal College of Surgeons in Ireland</gtr:name><gtr:address><gtr:line1>Academic Centre</gtr:line1><gtr:line2>Coombe Women's Hospital</gtr:line2><gtr:line3>Dublin 8</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3923DFCB-BCB6-4B65-BA04-DBFFDD0A5B22"><gtr:id>3923DFCB-BCB6-4B65-BA04-DBFFDD0A5B22</gtr:id><gtr:name>British Lung Foundation (BLF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4914A80B-E40B-47C2-B6A2-D52F06FE6DA1"><gtr:id>4914A80B-E40B-47C2-B6A2-D52F06FE6DA1</gtr:id><gtr:firstName>Marion</gtr:firstName><gtr:surname>MacFarlane</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U132685863"><gtr:id>106C9D44-61A5-4B20-B781-84AF387340EF</gtr:id><gtr:title>Molecular Mechanisms of Cell Death and their role in Cellular Toxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U132685863</gtr:grantReference><gtr:abstractText>Diseases such as cancer and neurodegenerative disorders are characterised by a significant alteration in the total number of cells within the tissue. This may result from increased division of cells and/or may arise from a defect in cell death regulation within the target tissue. In tissues, such as the lymphoid system or the colon, cell death is very important as it controls the total number of cells within that tissue whereas in the nervous system inappropriate cell death is catastrophic. Consequently, cell death in these situations is tightly controlled and often occurs in an ordered manner by a process called ?apoptosis?. We are studying the process of apoptosis specifically in tumour cells because to successfully treat many cancers it is important that we find ways to switch ?ON? this important cell death pathway. Most cytotoxic drugs and some naturally occurring proteins, called ?death ligands? can trigger tumour cells to die by apoptosis, although other modes of cell death (e.g. necrosis) can also be activated. It is therefore important to first understand the basic mechanisms that regulate cell death in order to identify ways of selectively killing tumour cells while leaving most healthy cells unharmed. We are trying to understand the fundamental mechanisms that regulate the response of tumour cells and normal cells to cytotoxic agents as this will help in establishing the ideal combination of these inherently toxic agents for the treatment of cancer that relies on re-activation of the tumour?s own cell death machinery. Importantly, by adopting a rational systems-based approach to assess the combined use of cytotoxic agents we also aim to minimise the risk of adverse toxic side effects in certain patients.</gtr:abstractText><gtr:technicalSummary>This programme aims at further understanding the fundamental mechanisms of cell death that regulate cellular resistance/sensitivity to toxic insult. The MRC Toxicology Unit strategy is to employ a systems-based approach to determine the pathways that are initiated following exposure of cells/organisms to a range of toxic insults. However, defined nodes that form the key decision points to regulate the pathways that respond to toxic injury have been identified and these include proteins that control cell death. The objective of this programme is to investigate cell death pathways that are activated in response to a range of agents, namely members of the TNF cytokine family and agents that trigger mitochondrial-dependent cell death. Using unbiased high throughput screening approaches we aim to define key changes in mRNA/miRNA/proteins in cells undergoing distinct modes of cell death (e.g. apoptosis versus programmed necrosis). In addition, we will use targeted pathway analysis and mechanism-based approaches to obtain novel mechanistic insights so that key regulators can be identified and their potential role in cellular toxicity determined. 
Our Specific Objectives are:
1. Systems-based identification/characterization of novel modulators of cell death pathways 

2. Molecular characterization of the DISC and key regulators of death receptor signalling 

3. To examine mechanisms of selective potentiation of cell death in primary tumour models

4. Dissecting mechanisms of apoptosis resistance in asbestos-induced malignant mesothelioma</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>7959290</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Cell Biology</gtr:department><gtr:description>Primary Lung Tumour Explant Model</gtr:description><gtr:id>929AE214-41A3-4E11-B8B9-18D8E9A9B341</gtr:id><gtr:impact>Joint MRC-funded DTG Studentship Award
Future joint senior author publications</gtr:impact><gtr:outcomeId>LohdVX4gUzD-1</gtr:outcomeId><gtr:partnerContribution>International expertise in Cell Signalling Pathways and the development of in vivo mouse models of Lung Cancer</gtr:partnerContribution><gtr:piContribution>Previous experience in culturing Breast tumour tissue ex-vivo has now been applied in a collaborative project on NSCLC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal College of Surgeons in Ireland</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Characterisation of a non-canonical caspase-8 activation complex in response to impaired proteasomal protein degradation</gtr:description><gtr:id>4DF43CE0-4FA0-4C74-A0A5-A91FD5B68E2A</gtr:id><gtr:impact>EMBO Short-term Fellowship Award (3-months) to Dr Christian Hellwig (RCSI, Dublin) - July to Sept 2013.</gtr:impact><gtr:outcomeId>htFqatfcw4i-1</gtr:outcomeId><gtr:partnerContribution>Non-canonical caspase-8 activation model and systems biology analysis of caspase activation</gtr:partnerContribution><gtr:piContribution>Expertise on Isolation and Characterisation of Multiprotein Cell Death Signalling Complexes</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy</gtr:department><gtr:description>Abberrant Translational Regulation in NHL</gtr:description><gtr:id>0DDECD4B-9CD4-4095-88F9-8534CEF729B6</gtr:id><gtr:impact>As co-applicant, secured funding from LLR for PDRA 
(Oct, 2008 - April, 2011)
Future Joint Senior Author Publications</gtr:impact><gtr:outcomeId>MLHUK1YQvrE-1</gtr:outcomeId><gtr:partnerContribution>Internationally recognised expertise on Mechanisms of Translational Regulation</gtr:partnerContribution><gtr:piContribution>Provided expertise on fundamental mechanisms of cell death</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Lung Foundation (BLF)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Predicting Sensitivity to PI3K/mTOR Inhibition in Malignant</gtr:description><gtr:id>B6054516-C976-465E-B8C3-898196A0A341</gtr:id><gtr:impact>Secured funding from British Lung Foundation - Project Award on Asbestos-related Disease - &amp;pound;185,000 - June 2013.</gtr:impact><gtr:outcomeId>H8DAcFxwVbn-2</gtr:outcomeId><gtr:partnerContribution>Access to Malignant Mesothelioma patient samples and clinical trial portfolio</gtr:partnerContribution><gtr:piContribution>In vitro models of malignant mesothelioma and tools to explore mechanisms of cell death</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Biology GSK</gtr:department><gtr:description>Investigating the role of TRAIL in resolving Allergen-Induced Inflammation</gtr:description><gtr:id>574DE575-ED48-4A21-910A-DECCF08E8B10</gtr:id><gtr:impact>MRC I-CASE Studentship Award 2011-2015</gtr:impact><gtr:outcomeId>i9JvfNWMRoK-1</gtr:outcomeId><gtr:partnerContribution>Secured MRC I-CASE Award with GSK</gtr:partnerContribution><gtr:piContribution>Providing host lab for MRC I-CASE Award.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>The role of Mcl-1 in the co-ordinated regulation of apoptosis and autophagy</gtr:description><gtr:id>8F9567D3-E2D1-4530-9E17-244E5FBE669D</gtr:id><gtr:impact>This collaboration has just started - Oct 2014</gtr:impact><gtr:outcomeId>54638adc5c39b7.29569041-1</gtr:outcomeId><gtr:partnerContribution>GSK have available a number of tool compounds that have exhibited potential adverse effects in tissues where the underlying mechanisms of toxicity appear centred around the regulation of apoptosis and autophagy at the level of mitochondria by the anti-apoptotic protein Mcl-1.</gtr:partnerContribution><gtr:piContribution>We have extensive expertise in exploring the fundamental mechanisms of cell death and autophagy and thus will provide valuable novel insight to this area of research within GSK Toxicology division.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heidelberg University</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Mannheim Faculty of Medicine</gtr:department><gtr:description>Characterisation of the Ripoptosome Complex induced by TLRs</gtr:description><gtr:id>F4AC1206-472F-4004-B37F-A8B3AC7D6C3E</gtr:id><gtr:impact>Joint research publication in Molecular Cell</gtr:impact><gtr:outcomeId>txcdPVJWBMd-1</gtr:outcomeId><gtr:partnerContribution>Publication of a joint research paper in Molecular Cell (2011)</gtr:partnerContribution><gtr:piContribution>Provided expertise on characterisation of large multi-protein cell death signalling complexes.
Carried out experiments to characterise the Ripoptosome by gelfiltration chroamtography, Ip and Western blot analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Drug Safety Science</gtr:department><gtr:description>Cell Death Mechanisms underlying the Toxicity of Anti-Malarials</gtr:description><gtr:id>96DD8A2A-5EDA-469C-8E76-0F172A2FAB83</gtr:id><gtr:impact>Awarded Joint MRC ITTP Studentship
Future Joint Senior Author Publications</gtr:impact><gtr:outcomeId>pJ7kpsNbgC7-1</gtr:outcomeId><gtr:partnerContribution>International expertise on Toxicity of Anti-malarials and design of novel anti-malarials with improved safety</gtr:partnerContribution><gtr:piContribution>Expertise on fundamental Mechanisms of Cell Death and Mitochondrial Toxicity</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>Investigating the Potential Adverse Effects of Novel IAP Antagonists</gtr:description><gtr:id>084ECAF8-9291-4D10-AC6C-441ED17ABAA3</gtr:id><gtr:impact>MRC ITTP Studentship Award</gtr:impact><gtr:outcomeId>WeDqkxSj7x9-1</gtr:outcomeId><gtr:partnerContribution>Newcastle - access to pluripotnet liver cells/animal models</gtr:partnerContribution><gtr:piContribution>Molecular analysis of cell death activity of IAP antagonists</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Characterisation of the Ripoptosome Complex Induced by Genotoxic Stress</gtr:description><gtr:id>D8900ED6-C2B8-4E53-BF58-9FB97933407C</gtr:id><gtr:impact>Joint research publication (Mol Cell)</gtr:impact><gtr:outcomeId>PyoPWFbZ2uA-1</gtr:outcomeId><gtr:partnerContribution>Publication of joint reserach paper in Molecular Cell (2011).</gtr:partnerContribution><gtr:piContribution>Provided expertise on characterising large cell death signalling complexes. Experiments to characterise the Complex by gel filtration, IP and Western blotting.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aberdeen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Applied Medicine</gtr:department><gtr:description>Investigating the Potential Adverse Effects of Novel IAP Antagonists</gtr:description><gtr:id>6B1A9134-D02D-414A-BA71-6AD6D83232A9</gtr:id><gtr:impact>MRC ITTP Studentship Award</gtr:impact><gtr:outcomeId>WeDqkxSj7x9-2</gtr:outcomeId><gtr:partnerContribution>Newcastle - access to pluripotnet liver cells/animal models</gtr:partnerContribution><gtr:piContribution>Molecular analysis of cell death activity of IAP antagonists</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cancer Studies</gtr:department><gtr:description>Predicting Sensitivity to PI3K/mTOR Inhibition in Malignant</gtr:description><gtr:id>2EC132D6-387E-49FF-94CC-AADCF273C13F</gtr:id><gtr:impact>Secured funding from British Lung Foundation - Project Award on Asbestos-related Disease - &amp;pound;185,000 - June 2013.</gtr:impact><gtr:outcomeId>H8DAcFxwVbn-1</gtr:outcomeId><gtr:partnerContribution>Access to Malignant Mesothelioma patient samples and clinical trial portfolio</gtr:partnerContribution><gtr:piContribution>In vitro models of malignant mesothelioma and tools to explore mechanisms of cell death</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Cell Biology</gtr:department><gtr:description>Structural Modelling of Death Receptor Signalling Platforms</gtr:description><gtr:id>F9EC1E5D-D712-4F48-A4C8-6893D3375D4B</gtr:id><gtr:impact>Manuscript Published in Molecular Cell - ID 22683266</gtr:impact><gtr:outcomeId>QbGXcH6LwWs-1</gtr:outcomeId><gtr:partnerContribution>Structural Modelling of Death Receptor Signalling Components</gtr:partnerContribution><gtr:piContribution>Intellectual Input on Death Receptor Signalling Platforms</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>Mouse Model of asbestos and carbon nanotube-induced Inflammation/Proliferation</gtr:description><gtr:id>712E67C3-D2F3-450A-B3DC-01F26AD38636</gtr:id><gtr:impact>Poster and Short Talk as well as Invited Talk Presentations at iMig Conference 2012 (Boston, USA), BTS Annual Congress 2012, Inhaled Particles XI 2013 (Nottingham), 10th International Particle Toxicology Conference 2013 (Dusseldorf, GER), World Lung Cancer Conference 2013 (Sydney, AUS); Manuscripts in preparation.</gtr:impact><gtr:outcomeId>p9qQZ9bbSC4-1</gtr:outcomeId><gtr:partnerContribution>Unique access to animal model/pleural instillation/Intellectual Input on hazard mechanism of carbon nanotubes</gtr:partnerContribution><gtr:piContribution>Provide molecular profiling of pleural tissues/Intelleactual Input on hazard mechanism of carbon nanotubes</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Visit, Leicester</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>20D9FD39-8612-4A79-B12C-3827BA684C23</gtr:id><gtr:impact>30 school pupils attended a 'Science in a Box' Presentation

School requested visit from Unit Scientists</gtr:impact><gtr:outcomeId>ebqCFCn767u</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Podcast - August 2009 (www.genengnews.com)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB8B8098-3E59-4B84-B982-C806A49096D9</gtr:id><gtr:impact>Podcast (www.genengnews.com) - MRC PI Interviewed by Editor in Chief of Genetic Engineering &amp;amp; Biotechnology News re. recent Publication in Molecular Cell highlighted in MRC Media Release (MRC/52/09)

Feedback received by MRCT regarding DISC Invention</gtr:impact><gtr:outcomeId>675AA549AA6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.genengnews.com</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cell Press Journal Cover Release (Our DISC Model Selected for Publication on Cover of Molecular Cell (22683266) - July 2012)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>807E128C-058B-43D9-B453-21C841DD8BDB</gtr:id><gtr:impact>Cell Press release highlighting the slection and publication of our new DISC Model based on DED Chains on the Cover of Molecular Cell (PubMed ID 22683266)

Significant Publicity for MRC-funded Research</gtr:impact><gtr:outcomeId>ZJabwuu5WQf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Day - MRC Toxicology Unit - 22 June 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C0513A02-65B0-48B2-9DDA-9083B308A540</gtr:id><gtr:impact>500 people attended the MRC Toxicology Unit 'MRC Centenary Open Day' - 22 June 2013.

Local schoolchildren asked for additional visits to the MRC Toxicology Unit to gain some lab experience.</gtr:impact><gtr:outcomeId>pjQ1Ri8tbSt</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://tox.mrc.ac.uk/2013/06/mrc-toxicology-unit-centenary-open-day-was-a-great-success-with-the-public/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC (MRC/52/09)/University of Leicester Media Release 13 August 2009</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A5CA3CB-6982-4F48-A343-732044CF6F47</gtr:id><gtr:impact>MRC Media Release (MRC/52/09) - 13 August 2009: 'MRC Scientists Advance Understanding of Cell Death'

Request received from Editor in Chief of 'Genetic Engineering &amp;amp; Bioctechnology News' for Podcast Interview with MRC PI</gtr:impact><gtr:outcomeId>25D4E434696</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Postgraduate Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9F606E45-B404-4812-93CB-BDB4CA5FE91C</gtr:id><gtr:impact>Two reserach students from my group presented their work to a lay audiense inclusing the Public and other sectors 
(Poster Presentaions)

One research student was 'highly commended' for her presentation content and style</gtr:impact><gtr:outcomeId>S33Mgk5Tptn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Annual Review 2009-2010, Section 5, p20 'Understanding cell death'</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1BAC68FC-9415-44A2-8B52-01BFDACA28C9</gtr:id><gtr:impact>Information about our work on reconstituting the CD95 DISC was highlighted in the MRC Annual Review 2009-2010, Section 5
'Understamding Cell Death'

Informed the public and other audiences of our work.</gtr:impact><gtr:outcomeId>piGHnv8eodm</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC-Industrial Showcase - Poster Presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DDA5995C-82E5-43BF-828A-1669214DC7A3</gtr:id><gtr:impact>MRC-Industrial Showcase-Advances in Oncology &amp;amp; Cancer, Alderley Park, Cheshire, 21-22 Nov, 2008. Primarily to showcase our work in this area to potential partners in Industry.

Subsequent funding of DGF Project by MRCt</gtr:impact><gtr:outcomeId>617AC0471CC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Annual Review 2007-2008, p56-57</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D961F77A-4F4D-4530-BA1D-983E013415A9</gtr:id><gtr:impact>Information about our work on TRAIL Mutants was highlighted in the MRC Annual Review, 2007-2008, Pages 56-57.

Informed public and other audiences of our work.</gtr:impact><gtr:outcomeId>1F28D13F89C</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (Lutterworth)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>69CD6489-F1C0-4C07-A310-CC5C75264FCA</gtr:id><gtr:impact>Two members of my team (CDFs) visited a local School to host 'Lab in a Box' activity

Pupils have requested to visit MRC Toxicology Unit Open Day, 2013</gtr:impact><gtr:outcomeId>Sg5x35kJRx9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Funding for MRC-UoL-CRT Explant Consortium</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Cancer Research Technology (CRT)</gtr:fundingOrg><gtr:id>5C853B64-F914-4929-916E-33BB29659B2E</gtr:id><gtr:outcomeId>58ca4e6beef9a3.87807640</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>92838</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC I-CASE Award (with GSK)</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6C4011FF-0459-4A7D-BDEC-49FD3D7C2E83</gtr:id><gtr:outcomeId>kqt4s7subLs0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170616</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR Project Grant (Understanding the role of elF4B in the pathogenesis of Diffuse Large B-Cell Lymphoma)</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:fundingRef>14023</gtr:fundingRef><gtr:id>D1747952-B3D8-4D7E-B4B0-EECD15FA014F</gtr:id><gtr:outcomeId>54639134a41e89.83319054</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Fund</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>A788DB65-E756-4465-A32C-1F7E51EDFC5D</gtr:id><gtr:outcomeId>9326D3C199E0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Research and Development AstraZeneca</gtr:department><gtr:description>AZ iMED PostDoctoral Funding Scheme</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>EEA8841F-E740-4441-A199-516FA7E842A0</gtr:id><gtr:outcomeId>58ca4f2a46d189.40458879</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Integrative Training Partnership in Toxicology (ITTP)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A33EE371-A409-47DA-A390-ACCE3E1CB9FB</gtr:id><gtr:outcomeId>5E75A131FCA0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC-funded Doctoral Training Award</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8E9883EB-2780-44BA-9EAC-D9DF504603D1</gtr:id><gtr:outcomeId>Ag8kQ9zFxkM0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EMBO Short-Term Fellowship (Characterisation of a non-canonical caspase-8 activation complex in response to impaired proteasomal protein degradation)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>European Molecular Biology Organisation</gtr:fundingOrg><gtr:id>DF7FE30B-C0DA-4472-B55E-779E659296F8</gtr:id><gtr:outcomeId>afwP2yxYKMv</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>167000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR Project Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>3FD15B20-7118-43B9-9E2F-BCB21A113CE6</gtr:id><gtr:outcomeId>dkXtav3upDu0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118126</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC I-CASE Award (with GSK)</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BBSRC BB/M502819/1</gtr:fundingRef><gtr:id>86F9F597-4884-49E1-96AF-84F615AFE3D7</gtr:id><gtr:outcomeId>54639052e4ebe9.95041041</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BLF Project Award (Predicting Sensitivity to PI3K/mTOR Inhibition in Malignant Mesothelioma)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:fundingRef>APG13-6</gtr:fundingRef><gtr:id>8F4DCEDF-A3C4-4822-BA5E-7EEAC212117F</gtr:id><gtr:outcomeId>QvUKLwhSdTo</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Integrative Training Partnership in Toxicology (ITTP)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0928F582-808B-47F3-95C5-AC2AF14CD6F4</gtr:id><gtr:outcomeId>RnMTaSWL43M</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Our laboratory generated Receptor-selective TRAIL Mutants and using these agents determined that primary Tumour cells primarily signal to TRAIL-induced apoptosis via TRAIL-R1</gtr:description><gtr:grantRef>MC_U132685863</gtr:grantRef><gtr:id>6476585F-8E95-447C-B0EB-6539AF24CD62</gtr:id><gtr:impact>Licensed outside UK - International - US</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>39EBB61E0D8</gtr:outcomeId><gtr:patentId>US2009325867</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Receptor-Specific TRAIL Variants (PCT/GB2006/004461)</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Our laboratory reconstituted the Death-Inducing Siganling Complex (DISC) for the very first time in vitro, thus providing a valable tool for kit formation, drug discovery and basic mechanistic studies relevant to human disease.</gtr:description><gtr:grantRef>MC_U132685863</gtr:grantRef><gtr:id>152C1BD9-BC43-499D-B0AF-ED4497332355</gtr:id><gtr:impact>Potential interest from commercial sector for adaptation to kit formulation is currently being explored by MRCT.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>AE628CDCEFA</gtr:outcomeId><gtr:patentId>US2009325867</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Reconstituted DISC Invention (IDF Ref# A856/2276)</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Reconstituted DISC Model being developed for use in a kit format for potential commercialization to assess the impact of key mutations in DISC components that are associated with human disease.</gtr:description><gtr:id>63667EA1-EEF2-4FC0-9F9F-3436C286C763</gtr:id><gtr:impact>MRCT have received interest from the commercial sector for a reconstituted DISC in 'kit format'</gtr:impact><gtr:outcomeId>0968911445C</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Reconstituted DISC Invention (IDF Ref# A856/2276)</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>TRAIL Mutants designed within the MRC Toxicology Unit and patented by MRCT are currently being tested in relevant preclinical models of breast cancer. Previous work has provided proof of concept of the efficacy of these TRAIL Mutants in primary haematological malignancies and identified a critical requirement for employing TRAIL-R1-specific mutant forms of TRAIL in any potential therapy employing soluble TRAIL in these patients.</gtr:description><gtr:id>E17DFE37-F879-4477-B5C2-1A87694ED55E</gtr:id><gtr:impact>Our work to date, plus our ongoing studies funded by the MRCT DGF in preclinical models of breast cancer, have helped provide a rational approach to optimize TRAIL therapy (either alone or in combination).</gtr:impact><gtr:outcomeId>3B0836E0F5E</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Receptor-specific TRAIL Variants (PCT/GB2006/004461)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have generated the very first Locus Specific Database (LSVD) housing all known Variants of the TRAIL Receptors. This is a publically available database providing invaluable identifiable information on the pathogenic potential of TRAIL-R variants</gtr:description><gtr:id>2BF8067A-A66E-4278-B05D-1B238E7A6F45</gtr:id><gtr:impact>Collaborative Manuscript currently in preparation</gtr:impact><gtr:outcomeId>YoYTia5mPd9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Locus Specifc Database (LSBD) titled DRdb</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Over the last 5 years we have developed a novel in vitro reconstituton model of a siganaling complex called the DISC which regulates the susceptibility of cells to apoptosis induced by death ligands such as CD95 or TRAIL. This novel in vitro DISC model enables us to examine the key steps that regulate DISC formation and activity in both normal and tumour cells. This model was recently published in Molecular Cell (PubMed ID# 19683492), a patent has been filed by MRCT (A856/2276) and this information was also highlighted in an MRC Media Release (MRC/52/09) and the MRC Annual Review, 2009-2010.</gtr:description><gtr:id>2A8FA1E9-061E-41E7-855F-5E0C20ADFD74</gtr:id><gtr:impact>This tool could provide a screen to assay for small molecule regulators of DISC activity so it has the potential not only to provide fundmental mechansistic insights but also identify potential novel regulators of DISC activity using a HTP approach and is amenable to kit formulation.</gtr:impact><gtr:outcomeId>3D62B36E68F</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Reconstituted DISC Model</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9893511F-1B04-4B83-903C-1C5E6D82C11B</gtr:id><gtr:title>MesobanK UK: an international mesothelioma bioresource.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2cb1ebd10191ec62e0de95636367469"><gtr:id>f2cb1ebd10191ec62e0de95636367469</gtr:id><gtr:otherNames>Rintoul RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58ca4c0eee27f3.72635611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989F847E-8D8A-48DD-825B-5C6E3046B60D</gtr:id><gtr:title>Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cf3c7f03f6271218f79ff9e67caedeb"><gtr:id>5cf3c7f03f6271218f79ff9e67caedeb</gtr:id><gtr:otherNames>Volkmann X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>B9BE3B4F258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9AE92CE-B1D0-4383-89FC-D3EEDAA2352B</gtr:id><gtr:title>Pulmonary toxicity of carbon nanotubes and asbestos - similarities and differences.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5450166eb4110cf16c08031bdfbb1eb7"><gtr:id>5450166eb4110cf16c08031bdfbb1eb7</gtr:id><gtr:otherNames>Donaldson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>pm_15160_20_23899865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B19766A7-22E8-4674-8682-6E2E78036E57</gtr:id><gtr:title>Long-fibre carbon nanotube- and asbestos-induced pleural lesions exhibit a common molecular signature</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92956c6fe51a23b4b6910729cab1c99b"><gtr:id>92956c6fe51a23b4b6910729cab1c99b</gtr:id><gtr:otherNames>Murphy F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>5aaa8544a6d711.03585225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>733885CC-1173-41B7-94AA-C43C61929808</gtr:id><gtr:title>Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42dd50d6a147ddbe48323bf4f1e247da"><gtr:id>42dd50d6a147ddbe48323bf4f1e247da</gtr:id><gtr:otherNames>Chernova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>5aaa837d1aca67.77626998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF52BFFB-6CE9-4A9D-B113-56065786544D</gtr:id><gtr:title>Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfa9dc86a36cc76dee80d1191796e2ec"><gtr:id>dfa9dc86a36cc76dee80d1191796e2ec</gtr:id><gtr:otherNames>Williams AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>68255B8CA9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE9C4BD6-42A0-4D10-8179-8203403AC2E9</gtr:id><gtr:title>Biochemical Analysis of Initiator Caspase-Activating Complexes: The Apoptosome and the Death-Inducing Signaling Complex.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10b32a5dce1d05826b424fd05ffc06a7"><gtr:id>10b32a5dce1d05826b424fd05ffc06a7</gtr:id><gtr:otherNames>Langlais C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1559-6095</gtr:issn><gtr:outcomeId>56e0adf4afc343.53660003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A4530CC-64B0-462C-B118-1C5D35E0CA96</gtr:id><gtr:title>TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3f2b00254fefc176c70ca61cec715ed"><gtr:id>c3f2b00254fefc176c70ca61cec715ed</gtr:id><gtr:otherNames>Stadel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>kFrXwFGPFUr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AF342FF-964D-4A27-A59A-C877766DDDE7</gtr:id><gtr:title>Isolation, characterisation and reconstitution of cell death signalling complexes.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8586545a7debb2a2b47fa2bfe7a5b80b"><gtr:id>8586545a7debb2a2b47fa2bfe7a5b80b</gtr:id><gtr:otherNames>Hughes MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>pm_15160_20_23485576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708000B5-17AB-4E64-9E65-480186019CD5</gtr:id><gtr:title>Activation, Isolation, and Analysis of the Death-Inducing Signaling Complex.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8586545a7debb2a2b47fa2bfe7a5b80b"><gtr:id>8586545a7debb2a2b47fa2bfe7a5b80b</gtr:id><gtr:otherNames>Hughes MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1559-6095</gtr:issn><gtr:outcomeId>56e0adf493cbb0.77727568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07B70AC3-5729-4F55-AB7E-F0B751422FCD</gtr:id><gtr:title>A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c6c1655c42be2ee4f690159ce345e7e"><gtr:id>3c6c1655c42be2ee4f690159ce345e7e</gtr:id><gtr:otherNames>Horvilleur E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>54637b2685c183.10252772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36A17512-9F7F-414B-93ED-686D28727540</gtr:id><gtr:title>A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9ab7e251886761e1d6d7b399acc6f26"><gtr:id>a9ab7e251886761e1d6d7b399acc6f26</gtr:id><gtr:otherNames>Simpson KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_15160_20_23640455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2F773F2-073D-492E-A8CC-17E1A8B7BD0E</gtr:id><gtr:title>TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7646eb6d6d6dc2890439db5ed02c07"><gtr:id>4a7646eb6d6d6dc2890439db5ed02c07</gtr:id><gtr:otherNames>Natoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>3D51FB1DAFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F82CC83-4EAD-43EF-8773-5E481C005924</gtr:id><gtr:title>Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb84028954a3fffabe84d3f8a4385ec2"><gtr:id>bb84028954a3fffabe84d3f8a4385ec2</gtr:id><gtr:otherNames>Young KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>AawSf1mSWJY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>766D270A-7EBB-4738-8DA1-C4197512A8D8</gtr:id><gtr:title>Targeting the rate limiting step of protein synthesis may provide an alternative approach to overcome the chemoresistance of malignant mesothelioma</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f640397c55fa0c94440ba0c8f8e482ba"><gtr:id>f640397c55fa0c94440ba0c8f8e482ba</gtr:id><gtr:otherNames>Grosso S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546386f6b1d300.80291998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6BA3E5C-AADC-455F-BE4F-FF8B90F724E7</gtr:id><gtr:title>Notch4 Signaling Confers Susceptibility to TRAIL-Induced Apoptosis in Breast Cancer Cells.</gtr:title><gtr:parentPublicationTitle>Journal of cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcdd52a1d70ab07b58a3b4d62f15c6d6"><gtr:id>fcdd52a1d70ab07b58a3b4d62f15c6d6</gtr:id><gtr:otherNames>Naik S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0730-2312</gtr:issn><gtr:outcomeId>56e0a6d3c01831.53238937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93C175CA-0CC9-4EF2-BA0A-E5A8D4844B9E</gtr:id><gtr:title>The ripoptosome - a novel molecular complex differentially regulated by cFLIP isoforms and a critical switch between apoptotic and necroptotic cell death in skin tumor cells</gtr:title><gtr:parentPublicationTitle>EXPERIMENTAL DERMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22a02b726baf74a8409d2d0c71eb0b8a"><gtr:id>22a02b726baf74a8409d2d0c71eb0b8a</gtr:id><gtr:otherNames>Feoktistova M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0906-6705</gtr:issn><gtr:outcomeId>EoT1ZKUdqtS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3148CDDF-C519-4793-928E-9083F5755687</gtr:id><gtr:title>Barriers to effective TRAIL-targeted therapy of malignancy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>0C86A8DB620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3C7B112-7056-4704-8185-0697099A27EC</gtr:id><gtr:title>Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a619c8a2b289fe350a388acbe2938014"><gtr:id>a619c8a2b289fe350a388acbe2938014</gtr:id><gtr:otherNames>Melis MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>pm_15160_20_23412345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4353079-D991-4D42-B615-0EB905890E39</gtr:id><gtr:title>Co-operative and Hierarchical Binding of c-FLIP and Caspase-8: A Unified Model Defines How c-FLIP Isoforms Differentially Control Cell Fate.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8586545a7debb2a2b47fa2bfe7a5b80b"><gtr:id>8586545a7debb2a2b47fa2bfe7a5b80b</gtr:id><gtr:otherNames>Hughes MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>58ca4b67cd49f2.14233578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>724DC036-3EC3-4C69-AEB5-73D940408717</gtr:id><gtr:title>Role of pro-inflammatory cells in mesothelial cell oncogenesis induced by toxic fibres</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42dd50d6a147ddbe48323bf4f1e247da"><gtr:id>42dd50d6a147ddbe48323bf4f1e247da</gtr:id><gtr:otherNames>Chernova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546387c2ea0f27.58426101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>525A22B4-92EB-4E55-88EA-4D7C897CE90F</gtr:id><gtr:title>Disassembly of the JIP1/JNK molecular scaffold by caspase-3-mediated cleavage of JIP1 during apoptosis.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2da95512e44b71157147e62a8af926cd"><gtr:id>2da95512e44b71157147e62a8af926cd</gtr:id><gtr:otherNames>Vaishnav M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>nzTsxzaHmdi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>838E6339-D039-493F-A910-93150498188B</gtr:id><gtr:title>Cell death pathways--potential therapeutic targets.</gtr:title><gtr:parentPublicationTitle>Xenobiotica; the fate of foreign compounds in biological systems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee5e278971b823a5d03d1725b90f46d3"><gtr:id>ee5e278971b823a5d03d1725b90f46d3</gtr:id><gtr:otherNames>MacFarlane M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0049-8254</gtr:issn><gtr:outcomeId>E5F37F79824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC1AE99D-7022-4E18-9DF7-3B207D6B358E</gtr:id><gtr:title>Investigating the roles of lysosomal iron and reactive oxygen species in the onset of mitochondrial toxicity induced through endoperoxide antimalarial drugs</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/404dd6f6a0f4af27e38bb5a87e2112f3"><gtr:id>404dd6f6a0f4af27e38bb5a87e2112f3</gtr:id><gtr:otherNames>Firman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5463871b06a052.32845758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4048EB6-FC60-4620-8367-112A8A32FF33</gtr:id><gtr:title>Role of Pro-Inflammatory Cells in Development of Mesothelioma</gtr:title><gtr:parentPublicationTitle>JOURNAL OF THORACIC ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed8dc345116343cb252fbec7b23ae76d"><gtr:id>ed8dc345116343cb252fbec7b23ae76d</gtr:id><gtr:otherNames>Chernova Tatyana</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1556-0864</gtr:issn><gtr:outcomeId>5aaa86919e5f15.20521467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58BDCBD2-6C97-4790-A672-DFAA41C14BAB</gtr:id><gtr:title>Modulation of the sensitivity of Jurkat T-cells to inhibition of protein synthesis by tumor necrosis factor a-related apoptosis-inducing ligand.</gtr:title><gtr:parentPublicationTitle>Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c3b2bd5e01a751701f9c847195757bc"><gtr:id>3c3b2bd5e01a751701f9c847195757bc</gtr:id><gtr:otherNames>Elia A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1079-9907</gtr:issn><gtr:outcomeId>546388013150c7.12427177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EA1F7F4-079A-4512-943F-E3B18FB1C511</gtr:id><gtr:title>Assessing the cytotoxic profile of novel endoperoxide derivatives</gtr:title><gtr:parentPublicationTitle>Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/404dd6f6a0f4af27e38bb5a87e2112f3"><gtr:id>404dd6f6a0f4af27e38bb5a87e2112f3</gtr:id><gtr:otherNames>Firman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>cQfcQpYxyL2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>781BB297-F39F-4633-B1F5-1BF150D8334F</gtr:id><gtr:title>Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/362c1cb2879781fea4a783ff804f585f"><gtr:id>362c1cb2879781fea4a783ff804f585f</gtr:id><gtr:otherNames>Powley IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58c9ebab869440.91339118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AC6FD3F-E2A6-4760-BD40-7ACAD22AA6F4</gtr:id><gtr:title>An inducible caspase-3 &amp;quot;tumor death switch&amp;quot; model to identify circulating biomarkers of apoptotic cell death and test novel imaging probes for apoptosis</gtr:title><gtr:parentPublicationTitle>MOLECULAR CANCER THERAPEUTICS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb3334062fa125d3e38697fdb8727f65"><gtr:id>cb3334062fa125d3e38697fdb8727f65</gtr:id><gtr:otherNames>Taylor Kathryn L.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>7D4B0AABBFE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E1FFFFD-EE74-40F8-91C4-47E40C03755F</gtr:id><gtr:title>In Vitro Assembly and Analysis of the Apoptosome Complex.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10b32a5dce1d05826b424fd05ffc06a7"><gtr:id>10b32a5dce1d05826b424fd05ffc06a7</gtr:id><gtr:otherNames>Langlais C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1559-6095</gtr:issn><gtr:outcomeId>56e0adf4769bc8.65492581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>811D614B-1B24-4DB4-87E3-732D9728062A</gtr:id><gtr:title>Encyclopedia of Life Sciences</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee5e278971b823a5d03d1725b90f46d3"><gtr:id>ee5e278971b823a5d03d1725b90f46d3</gtr:id><gtr:otherNames>MacFarlane M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2001-01-01</gtr:date><gtr:isbn>0470016175</gtr:isbn><gtr:outcomeId>WKmcedgdxny</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>382C5411-C545-4E8F-B2B7-E39051D4506F</gtr:id><gtr:title>Recombinant TRAIL and TRAIL receptor analysis.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31adc5afb558620d7835d98bf4b8f3c2"><gtr:id>31adc5afb558620d7835d98bf4b8f3c2</gtr:id><gtr:otherNames>Harper N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>931D7ED16DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE36E2F5-9E5A-462A-9F82-6EF9A6CA3B6D</gtr:id><gtr:title>Resistance to HSP90 inhibition involving loss of MCL1 addiction.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32b9ab54e2703e237771e4986faa150a"><gtr:id>32b9ab54e2703e237771e4986faa150a</gtr:id><gtr:otherNames>Busacca S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56e0ab5314d776.63428778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8541DEDA-2F46-43C9-B50A-4A7FB88D4513</gtr:id><gtr:title>Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fd197c7387f34c8a9d8ee407e1493fd"><gtr:id>3fd197c7387f34c8a9d8ee407e1493fd</gtr:id><gtr:otherNames>Robinson GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_15160_20_22310286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FA36BB1-A19E-48EF-8174-2F2B60502EEA</gtr:id><gtr:title>Predicting sensitivity to PI3K/mTOR inhibition in asbestos-induced malignant mesothelioma models</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c43222c449343f470c63c54361a1543"><gtr:id>6c43222c449343f470c63c54361a1543</gtr:id><gtr:otherNames>Powley I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>5aaa8544dc66f1.22599169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDBDEDFA-5481-4119-986F-CE50C9797434</gtr:id><gtr:title>Doxorubicin synergises with a TRAIL-R1-specific ligand to selectively target TRAIL-resistant breast tumour cells for apoptosis</gtr:title><gtr:parentPublicationTitle>Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcdd52a1d70ab07b58a3b4d62f15c6d6"><gtr:id>fcdd52a1d70ab07b58a3b4d62f15c6d6</gtr:id><gtr:otherNames>Naik S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>j5hxf53XVAK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06BAB1B5-A4FE-450A-AD68-495319454546</gtr:id><gtr:title>The 'complexities' of life and death: death receptor signalling platforms.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af737d062fdce32a3932dc18cc9b476f"><gtr:id>af737d062fdce32a3932dc18cc9b476f</gtr:id><gtr:otherNames>Dickens LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>pm_15160_20_22542855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABA84FA9-956F-44CE-AF4F-AC34D5F602D3</gtr:id><gtr:title>Exposure to pathogenic fibres causes pro-oncogenic changes in the pleural cavity</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42dd50d6a147ddbe48323bf4f1e247da"><gtr:id>42dd50d6a147ddbe48323bf4f1e247da</gtr:id><gtr:otherNames>Chernova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54638782d4be87.71526431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1247DCF6-7828-4886-97C1-5185A543E16E</gtr:id><gtr:title>Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-?B Activation and Cell Survival.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dc3c0161cc73c474e94686250fe26e7"><gtr:id>3dc3c0161cc73c474e94686250fe26e7</gtr:id><gtr:otherNames>Horn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aaa82dcf2f477.29255926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC98461C-A5B0-419A-9B4D-1CD89B8DFF18</gtr:id><gtr:title>Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Cell death discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a88a1deedd271d6ba0f88a9725a5fcc5"><gtr:id>a88a1deedd271d6ba0f88a9725a5fcc5</gtr:id><gtr:otherNames>Watson AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2058-7716</gtr:issn><gtr:outcomeId>58c9ebac279743.04521365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5C64FE5-9298-41C6-BCEE-817344EB413A</gtr:id><gtr:title>Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42dd50d6a147ddbe48323bf4f1e247da"><gtr:id>42dd50d6a147ddbe48323bf4f1e247da</gtr:id><gtr:otherNames>Chernova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>56e0adf4d6e218.37390462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C51050F9-CADC-43E6-BB6C-07B50049B2A5</gtr:id><gtr:title>Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8586545a7debb2a2b47fa2bfe7a5b80b"><gtr:id>8586545a7debb2a2b47fa2bfe7a5b80b</gtr:id><gtr:otherNames>Hughes MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>7EFC2C18FBB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9348CCF7-85D6-4C1B-BB9A-A4A3D94DE955</gtr:id><gtr:title>Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f446e86d6836d8e6a5da49dfe563b87"><gtr:id>8f446e86d6836d8e6a5da49dfe563b87</gtr:id><gtr:otherNames>Galluzzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>5aaa83f9ce6274.30995402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAC42DB8-22E7-4B0A-B0CF-3CC9FF0FEFD7</gtr:id><gtr:title>Molecular evidence that metabolic reprogramming contributes to cell survival and chemoresistance in malignant mesothelioma</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/472da9529c9f003ed033d63c908c5297"><gtr:id>472da9529c9f003ed033d63c908c5297</gtr:id><gtr:otherNames>Sun X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>5aaa8545118c31.80765935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE8A8781-63D3-4266-94B9-09017BEE4110</gtr:id><gtr:title>A TRAIL-R1-specific ligand in combination with doxorubicin selectively targets primary breast tumour cells for apoptosis</gtr:title><gtr:parentPublicationTitle>Breast Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43e947dc2345d09f34cab9fb38c41c6a"><gtr:id>43e947dc2345d09f34cab9fb38c41c6a</gtr:id><gtr:otherNames>Twiddy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>H1oRjNavFgR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24B07619-A34C-4E7B-8587-E35811622446</gtr:id><gtr:title>cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/949d759f0e46b3cc7052411e2d9bfd02"><gtr:id>949d759f0e46b3cc7052411e2d9bfd02</gtr:id><gtr:otherNames>Feoktistova M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>QpcfLiachf6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5C4AC8C-ADF7-4CBB-8709-4CE639D6079C</gtr:id><gtr:title>Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb21aa48b34d485576459cda583d6cbe"><gtr:id>bb21aa48b34d485576459cda583d6cbe</gtr:id><gtr:otherNames>Karekla E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58c9ebab56a841.59865883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFA47398-5F5D-4CC5-80FB-59C1DB94C925</gtr:id><gtr:title>'Aerobically poised' leukaemia cells are resistant to the mitochondrial toxin and BCL-2/BCL-XL inhibitor, ABT-737</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20d830e87a5ab3f98da1adf9d7fa1e70"><gtr:id>20d830e87a5ab3f98da1adf9d7fa1e70</gtr:id><gtr:otherNames>Miles G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>5aaa86184c9f69.68017877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82C1A130-3AD2-4023-9184-B13E82610EA0</gtr:id><gtr:title>A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af737d062fdce32a3932dc18cc9b476f"><gtr:id>af737d062fdce32a3932dc18cc9b476f</gtr:id><gtr:otherNames>Dickens LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>pm_15160_20_22683266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4C1D6D0-ABF6-49E0-A5BC-6417D2C3CEA5</gtr:id><gtr:title>SMAC mimetics in combination with the pro-inflammatory cytokine TNFa augment cell death in B-13 progenitor-derived hepatocytes</gtr:title><gtr:parentPublicationTitle>Toxicology Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/403eb1ce3afcb32b6fa1dc8ebab6dc14"><gtr:id>403eb1ce3afcb32b6fa1dc8ebab6dc14</gtr:id><gtr:otherNames>Hayward G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-4274</gtr:issn><gtr:outcomeId>5aaa85c18b8a90.46987931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF6A9D4-60DC-4B37-BB5C-F7EA146DB3A9</gtr:id><gtr:title>Glucose--a sweet way to die: metabolic switching modulates tumor cell death.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee5e278971b823a5d03d1725b90f46d3"><gtr:id>ee5e278971b823a5d03d1725b90f46d3</gtr:id><gtr:otherNames>MacFarlane M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_15160_20_22983094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA4C2FCA-EC04-4CAC-9C20-2A1C07851D5D</gtr:id><gtr:title>Caspase-7 is directly activated by the approximately 700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 approximately 200-kDa complex.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43e947dc2345d09f34cab9fb38c41c6a"><gtr:id>43e947dc2345d09f34cab9fb38c41c6a</gtr:id><gtr:otherNames>Twiddy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CA1E5FE229B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06751892-F657-48FE-8208-22F2F5168773</gtr:id><gtr:title>Receptor-selective TRAIL Mutants Target Lymphoid Tumor cells for Apoptosis via TRAIL-R1: Implications for Therapy</gtr:title><gtr:parentPublicationTitle>Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee5e278971b823a5d03d1725b90f46d3"><gtr:id>ee5e278971b823a5d03d1725b90f46d3</gtr:id><gtr:otherNames>MacFarlane M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>D96E8510CAA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D2E5D4C-526A-4B67-84FE-2CE334896FE4</gtr:id><gtr:title>Targeting cell death signalling in cancer: minimising 'Collateral damage'.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dc434bc39e6e38d9509fbfbc1ffeb96"><gtr:id>9dc434bc39e6e38d9509fbfbc1ffeb96</gtr:id><gtr:otherNames>Fox JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58c9ebabb33282.70016293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40E881F7-4CC5-49EA-A53C-F5AAF83F7313</gtr:id><gtr:title>The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7184d0c1445b6690d81ba94a044cc29c"><gtr:id>7184d0c1445b6690d81ba94a044cc29c</gtr:id><gtr:otherNames>Tenev T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>pdn5dFmQtXS</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U132685863</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>